Moleac launches CognivAiD™, a novel targeted product for vascular dementia
CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular...
Moleac is proud to support Kythe Foundation
Moleac is proud to support Kythe Foundation, a Philippines-based non-profit organisation improving...
Moleac wins the 2022 Dun & Bradstreet Award for Business Eminence!
Moleac wins the 2022 Dun & Bradstreet Award for Business Eminence!The Dun & Bradstreet...
Our new product CognivAiD™!
Our new product CognivAiD™! Last Saturday 29 October, Moleac has launched its new product,...
NeuroAiD™II Dinner Symposium 2022
Thank you for your participation to our NeuroAiD™II Dinner Symposium alongside the World Stroke...
Moleac is at World Stroke Congress (WSC) in Singapore!
Moleac is at the World Stroke Congress (WSC) in Singapore! Visit us at Booth 25 and talk with our...
ISRRA meeting in Vienna
Moleac was honoured to support the International Stroke Recovery and Rehabilitation Alliance...
Moleac’s 20th Anniversary
Moleac celebrates its 20th Anniversary! We are proud of what we have achieved over the past 20...
World Stroke Day 2022
World Stroke Day is approaching! At Moleac, we are committed to increase stroke awareness and to...
Moleac is a certified Eco Office by the Singapore Environment Council
Moleac is excited to annouce that out Singapore office has been certified ECO-Office provided by...
NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
Singapore, June 6, 2022, Moleac is pleased to announce the release of the results of the SATURN...
NeuroAiD™II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, January 22 Moleac is pleased to announce the release of the ATHENE study results,...
Moleac Pte Ltd wins SBR National Business Award for Pharmaceuticals
SINGAPORE, MAY 2021 Moleac, a biopharmaceutical company based in Singapore, wins SBR National...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery
SINGAPORE, APRIL 21 Moleac, a biopharmaceutical company based in Singapore, announced the approval...
ESOC 2020: Abstracts on NeuroAiD
In November 2020, ESO-WSO provided scientific updates to Health Care Practitioners. During this...
Embracing World Stroke Day 2020
World Stroke Day 2020 Stroke remains one of the main cause for disability worldwide. Moleac...
Highlights from Asia Pacific Stroke Organization (APSC) and World Congress of Neurology (WCN) Scientific Symposia
Two scientific symposia were conducted on the 2nd October 2019 and 29th October 2019. Multiple...
Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium
June 2019 A scientific symposium was held on the 24th May 2019, which aimed to share the advance...
Moleac holds two educational symposia on the management of Traumatic Brain Injury
March 2019 Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic...
NeuroAiD combined with rehabilitation has shown additive and sustained benefits on post-stroke recovery over 2 years after an initial 3-month treatment following stroke onset
More subjects on NeuroAiD™ improved to functional independence compared to placebo among subjects...
Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery
SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research...
NeuroAiD at ASEAN Neurological Association
Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) &...
NeuroAiD at Asia Pacific Stroke Conference
Renowned clinicians and researchers will present abstracts from the latest studies conducted on...
NeuroAiD at World Congress of Neurology
Moleac’s flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology...
NeuroAiD presentations at European Stroke Conference
NeuroAiD, Moleac’s main product, will be presented at the 26th European Stroke Conference on 24th...
NeuroAiD presentations at European Stroke Organisation Conference
NeuroAiD, Moleac’s main product, will be presented at the 3rd European Stroke Organisation...
Launch of NeuroAiD in Nigeria
Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be...
Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore
“Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a...
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study
Cerebrovasc Dis 2017; 43:36-42 Published by S. Karger AG, Basel This analysis from the CHIMES-E...
Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards
NeuroAiD™ has been named New Product Innovation of the Year by Frost & Sullivan. This award...
NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset
Moleac is pleased to announce the release of the CHIMES-E study results published online in the...
Archived News
Press Releases2015“Chinese Herbal Medicine May Have Delayed Benefit in Stroke” A press article...
Chinese Herbal Medicine May Have Delayed Benefit in Stroke
VIENNA, Austria — Long-term follow-up of a trial investigating a Chinese herbal supplement in...
